• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国肝肾综合征患者的住院死亡率:全国住院患者样本。

In-hospital mortality of hepatorenal syndrome in the United States: Nationwide inpatient sample.

机构信息

Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok 10400, Thailand.

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, United States.

出版信息

World J Gastroenterol. 2021 Dec 7;27(45):7831-7843. doi: 10.3748/wjg.v27.i45.7831.

DOI:10.3748/wjg.v27.i45.7831
PMID:34963745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8661379/
Abstract

BACKGROUND

Hepatorenal syndrome (HRS) is a life-threatening condition among patients with advanced liver disease. Data trends specific to hospital mortality and hospital admission resource utilization for HRS remain limited.

AIM

To assess the temporal trend in mortality and identify the predictors for mortality among hospital admissions for HRS in the United States.

METHODS

We used the National Inpatient Sample database to identify an unweighted sample of 4938 hospital admissions for HRS from 2005 to 2014 (weighted sample of 23973 admissions). The primary outcomes were temporal trends in mortality as well as predictors for hospital mortality. We estimated odds ratios from multi-level mixed effect logistic regression to identify patient characteristics and treatments associated with hospital mortality.

RESULTS

Overall hospital mortality was 32%. Hospital mortality decreased from 44% in 2005 to 24% in 2014 ( < 0.001), while there was an increase in the rate of liver transplantation ( = 0.02), renal replacement therapy ( < 0.001), length of hospital stay ( < 0.001), and hospitalization cost ( < 0.001). On multivariable analysis, older age, alcohol use, coagulopathy, neurological disorder, and need for mechanical ventilation predicted higher hospital mortality, whereas liver transplantation, transjugular intrahepatic portosystemic shunt, and abdominal paracentesis were associated with lower hospital mortality.

CONCLUSION

Although there was an increase in resource utilizations, hospital mortality among patients admitted for HRS significantly improved. Several predictors for hospital mortality were identified.

摘要

背景

肝肾综合征(HRS)是一种危及生命的疾病,在晚期肝病患者中。关于 HRS 患者住院死亡率和住院资源利用的趋势数据仍然有限。

目的

评估死亡率的时间趋势,并确定美国 HRS 住院患者死亡的预测因素。

方法

我们使用国家住院患者样本数据库,从 2005 年到 2014 年确定了 4938 例 HRS 住院患者(未加权样本,23973 例)。主要结果是死亡率的时间趋势以及住院死亡率的预测因素。我们使用多水平混合效应逻辑回归估计比值比,以确定与住院死亡率相关的患者特征和治疗方法。

结果

总体住院死亡率为 32%。2005 年的住院死亡率为 44%,2014 年降至 24%(<0.001),而肝移植(=0.02)、肾脏替代治疗(<0.001)、住院时间(<0.001)和住院费用(<0.001)的比率有所增加。多变量分析显示,年龄较大、饮酒、凝血障碍、神经障碍和需要机械通气与更高的住院死亡率相关,而肝移植、经颈静脉肝内门体分流术和腹腔穿刺术与更低的住院死亡率相关。

结论

尽管资源利用有所增加,但 HRS 住院患者的死亡率显著降低。确定了几个与住院死亡率相关的预测因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccbc/8661379/f4d0b68627da/WJG-27-7831-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccbc/8661379/f4d0b68627da/WJG-27-7831-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccbc/8661379/f4d0b68627da/WJG-27-7831-g001.jpg

相似文献

1
In-hospital mortality of hepatorenal syndrome in the United States: Nationwide inpatient sample.美国肝肾综合征患者的住院死亡率:全国住院患者样本。
World J Gastroenterol. 2021 Dec 7;27(45):7831-7843. doi: 10.3748/wjg.v27.i45.7831.
2
Inpatient Mortality Benefit with Transjugular Intrahepatic Portosystemic Shunt for Hospitalized Hepatorenal Syndrome Patients.经颈静脉肝内门体分流术治疗住院肝肾综合征患者的住院病死率获益。
Dig Dis Sci. 2020 Nov;65(11):3378-3388. doi: 10.1007/s10620-020-06136-2. Epub 2020 Feb 15.
3
Gender Disparity in Inpatient Mortality After Transjugular Intrahepatic Portosystemic Shunt Creation in Patients Admitted With Hepatorenal Syndrome: A Nationwide Study.肝肾综合征患者经颈静脉肝内门体分流术后住院死亡率的性别差异:一项全国性研究
J Am Coll Radiol. 2020 Feb;17(2):231-237. doi: 10.1016/j.jacr.2019.08.020. Epub 2019 Sep 18.
4
Hepatorenal syndrome in hospitalized patients with chronic liver disease: results from the Nationwide Inpatient Sample 2002-2012.慢性肝病住院患者的肝肾综合征:来自2002 - 2012年全国住院患者样本的结果
J Investig Med. 2016 Jan;64(1):33-8. doi: 10.1136/jim-d-15-00181. Epub 2015 Dec 16.
5
National Trends and Outcomes of Transjugular Intrahepatic Portosystemic Shunt Creation Using the Nationwide Inpatient Sample.利用全国住院患者样本分析经颈静脉肝内门体分流术创建的全国趋势和结果
J Vasc Interv Radiol. 2016 Jun;27(6):838-45. doi: 10.1016/j.jvir.2015.12.013. Epub 2016 Mar 7.
6
Impact of Palliative Care Services on Treatment and Resource Utilization for Hepatorenal Syndrome in the United States.姑息治疗服务对美国肝肾综合征治疗及资源利用的影响
Medicines (Basel). 2021 May 12;8(5):21. doi: 10.3390/medicines8050021.
7
Hepatorenal syndrome: a Nationwide Trend Analysis from 2008 to 2018.肝肾综合征:2008 年至 2018 年的全国趋势分析。
Ann Med. 2021 Dec;53(1):2018-2024. doi: 10.1080/07853890.2021.1998595.
8
Hepatorenal syndrome: a review.肝肾综合征:综述
Hepatogastroenterology. 2010 Sep-Oct;57(102-103):1279-84.
9
Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.2型肝肾综合征与顽固性腹水:经颈静脉肝内门体分流术在18例等待原位肝移植的晚期肝硬化患者中的作用
Hepatogastroenterology. 2003 Nov-Dec;50(54):1753-5.
10
Portosystemic Shunts: Stable Utilization and Improved Outcomes, Two Decades After the Transjugular Intrahepatic Portosystemic Shunt.门体分流术:经颈静脉肝内门体分流术后二十年,稳定应用与改善的结局
J Am Coll Radiol. 2015 Dec;12(12 Pt B):1427-33. doi: 10.1016/j.jacr.2015.06.037. Epub 2015 Sep 26.

引用本文的文献

1
Impact of timing of endoscopy on clinical outcomes in cirrhotic patients with esophageal variceal bleeding: a monocentric retrospective study from Vietnam.内镜检查时机对肝硬化食管静脉曲张出血患者临床结局的影响:一项来自越南的单中心回顾性研究
BMC Gastroenterol. 2025 Aug 7;25(1):565. doi: 10.1186/s12876-025-03989-7.
2
Therapeutic Potential of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Liver Disease: Focus on Cirrhosis.钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂在肝脏疾病中的治疗潜力:聚焦于肝硬化
Cureus. 2025 May 25;17(5):e84768. doi: 10.7759/cureus.84768. eCollection 2025 May.
3
Comparison of hepatorenal syndrome incidence and outcomes using previous and current diagnostic criteria in cirrhotic patients.

本文引用的文献

1
Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease: Impact on renal function.经颈静脉肝内门体分流术治疗肝硬化肝肾综合征 - 慢性肾脏病患者:对肾功能的影响。
Dig Liver Dis. 2022 Aug;54(8):1101-1108. doi: 10.1016/j.dld.2021.09.008. Epub 2021 Oct 5.
2
Advances in management of hepatorenal syndrome.肝肾综合征的治疗进展。
Curr Opin Nephrol Hypertens. 2021 Sep 1;30(5):501-506. doi: 10.1097/MNH.0000000000000730.
3
North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.
使用既往和当前诊断标准对肝硬化患者肝肾综合征发病率及预后的比较
Hepatol Forum. 2024 Sep 10;6(1):5-10. doi: 10.14744/hf.2023.2023.0067. eCollection 2025.
4
Outcomes among patients with hepatorenal syndrome based on hospital teaching and transplant status: Analysis of 159 845 hospitalizations.基于医院教学和移植状态的肝肾综合征患者的结局:对159845例住院病例的分析
JGH Open. 2023 Nov 27;7(12):848-854. doi: 10.1002/jgh3.12985. eCollection 2023 Dec.
5
Predictors of Short-term Mortality in Patients of Cirrhosis of Liver Presenting as Acute Kidney Injury: An In-hospital Prospective Observational Study.以急性肾损伤为表现的肝硬化患者短期死亡率的预测因素:一项住院前瞻性观察研究。
J Clin Exp Hepatol. 2023 Nov-Dec;13(6):989-996. doi: 10.1016/j.jceh.2023.05.017. Epub 2023 Jun 2.
6
Improving the Management of Hepatorenal Syndrome-Acute Kidney Injury Using an Updated Guidance and a New Treatment Paradigm.使用更新的指南和新的治疗模式改善肝肾综合征-急性肾损伤的管理
Gastroenterol Hepatol (N Y). 2023 Sep;19(9):527-536.
7
Distinct Subtypes of Hepatorenal Syndrome and Associated Outcomes as Identified by Machine Learning Consensus Clustering.通过机器学习共识聚类确定的肝肾综合征的不同亚型及相关结局
Diseases. 2023 Jan 27;11(1):18. doi: 10.3390/diseases11010018.
8
Management of Decompensated Cirrhosis in the Surgical ICU: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document.外科重症监护病房中失代偿期肝硬化的管理:美国创伤外科协会重症监护委员会临床共识文件
Trauma Surg Acute Care Open. 2022 Aug 1;7(1):e000936. doi: 10.1136/tsaco-2022-000936. eCollection 2022.
9
Effect of Hospital Teaching Status on Mortality and Procedural Complications of Percutaneous Paracentesis in the United States: A Four-Year Analysis of the National Inpatient Sample.美国医院教学状况对经皮穿刺腹腔穿刺术死亡率和手术并发症的影响:对全国住院患者样本的四年分析
Cureus. 2022 Jun 24;14(6):e26282. doi: 10.7759/cureus.26282. eCollection 2022 Jun.
北美门静脉高压经颈静脉肝内门体分流术实践推荐
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1636-1662.e36. doi: 10.1016/j.cgh.2021.07.018. Epub 2021 Jul 15.
4
End-stage liver disease: Management of hepatorenal syndrome.终末期肝病:肝肾综合征的管理。
Liver Int. 2021 Jun;41 Suppl 1:119-127. doi: 10.1111/liv.14866.
5
Development and validation of a prognostic model for patients with hepatorenal syndrome: A retrospective cohort study.开发和验证肝肾综合征患者的预后模型:一项回顾性队列研究。
World J Gastroenterol. 2021 May 28;27(20):2615-2629. doi: 10.3748/wjg.v27.i20.2615.
6
Impact of Palliative Care Services on Treatment and Resource Utilization for Hepatorenal Syndrome in the United States.姑息治疗服务对美国肝肾综合征治疗及资源利用的影响
Medicines (Basel). 2021 May 12;8(5):21. doi: 10.3390/medicines8050021.
7
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.腹水、自发性细菌性腹膜炎和肝肾综合征的诊断、评估及管理:美国肝病研究协会2021年实践指南
Hepatology. 2021 Aug;74(2):1014-1048. doi: 10.1002/hep.31884.
8
Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.特利加压素联合白蛋白治疗 1 型肝肾综合征。
N Engl J Med. 2021 Mar 4;384(9):818-828. doi: 10.1056/NEJMoa2008290.
9
Terlipressin has stood the test of time: Clinical overview in 2020 and future perspectives.特利加压素经受住了时间的考验:2020年临床概述及未来展望。
Liver Int. 2020 Dec;40(12):2888-2905. doi: 10.1111/liv.14703.
10
The impact of acute kidney injury on mortality and clinical outcomes in patients with alcoholic cirrhosis in the USA.在美国,急性肾损伤对酒精性肝硬化患者的死亡率和临床结局的影响。
Eur J Gastroenterol Hepatol. 2021 Jun 1;33(6):905-910. doi: 10.1097/MEG.0000000000001947.